Clostridium butyricum inhibits METTL3 expression in colorectal cancer cells by upregulating G protein-coupled receptor 3 (GPR3), leading to the downregulation of vimentin and vascular endothelial growth factor receptor 2 (VEGFR2). Here, KDR is linked to colorectal cancer.